Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-6036 in Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Jul 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 1, open-label trial of divarasib in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (7 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Adverse Events and Percentage of Participants With Dose-Limiting Toxicities. Started Jul 2020; status: active, not recruiting.
02
Drugs
divarasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04449874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04449874.